Deciphering comprehensive features of tumor microenvironment controlled by chromatin regulators to predict prognosis and guide therapies in uterine corpus endometrial carcinoma

Front Immunol. 2023 Mar 3:14:1139126. doi: 10.3389/fimmu.2023.1139126. eCollection 2023.

Abstract

Background: Dysregulation of chromatin regulators (CRs) can perturb the tumor immune microenvironment, but the underlying mechanism remains unclear. We focused on uterine corpus endometrial carcinoma (UCEC) and used gene expression data from TCGA-UCEC to investigate this mechanism.

Methods: We used weighted gene co-expression network analysis (WGCNA) and consensus clustering algorithm to classify UCEC patients into Cluster_L and Cluster_H. TME-associated CRs were identified using WGCNA and differential gene expression analysis. A CR risk score (CRRS) was constructed using univariate Cox and LASSO-Cox regression analyses. A nomogram was developed based on CRRS and clinicopathologic factors to predict patients' prognosis.

Results: Lower CRRS was associated with lower grade, more benign molecular subtypes, and improved survival. Patients with low CRRS showed abundant immune infiltration, a higher mutation burden, fewer CNVs, and better response to immunotherapy. Moreover, low CRRS patients were more sensitive to 24 chemotherapeutic agents.

Conclusion: A comprehensive assessment of CRRS could identify immune activation and improve the efficacy of UCEC treatments.

Keywords: DNA methylation; chromatin regulator; immunotherapy; prognostic model; tumor immune microenvironment; uterine corpus endometrial carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatin*
  • Endometrial Neoplasms* / genetics
  • Endometrial Neoplasms* / therapy
  • Female
  • Humans
  • Immunotherapy
  • Prognosis
  • Tumor Microenvironment / genetics

Substances

  • Chromatin

Grants and funding

This work was supported by the National Natural Science Foundation of China (Grant No.81903032).